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ABSTRACT
Benzo[a]pyrene is an important environmental
mutagen and carcinogen. Its metabolism in cells
yields the mutagenic, key ultimate carcinogen
7R,8S,9S,10R-anti-benzo[a]pyrene-7,8-dihydrodiol-9,
10-epoxide, (1)-anti-BPDE, which reacts via its 10-
position with N
2-dG in DNA to form the adduct (1)-
trans-anti-BPDE-N
2-dG. To gain molecular insights
into BPDE-induced mutagenesis, we examined
in vivo translesion synthesis and mutagenesis in
yeast cells of a site-specific 10S (1)-trans-anti-
BPDE-N
2-dG adduct and the stereoisomeric 10R
( )-trans-anti-BPDE-N
2-dG adduct. In wild-type
cells, bypass products consisted of 76% C, 14% A
and 7% G insertions opposite (1)-trans-anti-BPDE-
N
2-dG;and89%C,4%Aand4%Ginsertionsopposite
( )-trans-anti-BPDE-N
2-dG. Translesion synthesis
was reduced by  26–37% in rad30 mutant cells lack-
ing Polh, but more deficient in rev1 and almost totally
deficient in rev3 (lacking Polz) mutants. C insertion
opposite the lesion was reduced by  24–33% in
rad30 mutant cells, further reduced in rev1 mutant,
and mostly disappeared in the rev3 mutant strain.
The insertion of A was largely abolished in cells lack-
ing either Polh, Polz or Rev1. The insertion of G was
not detected in either rev1 or rev3 mutant cells. The
rad30 rev3 double mutant exhibited a similar pheno-
type as the single rev3 mutant with respect to transle-
sion synthesis and mutagenesis. These results show
that while the Polz pathway is generally required for
translesionsynthesisandmutagenesisofthe(1)-and
( )-trans-anti-BPDE-N
2-dG DNA adducts, Polh, Polz
and Rev1 together are required for G!T transversion
mutations, a major type of mutagenesis induced by
these lesions. Based on biochemical and genetic
results,wepresentmechanisticmodelsoftranslesion
synthesis of these two DNA adducts, involving both
the one-polymerase one-step and two-polymerase
two-step models.
INTRODUCTION
Polycyclic aromatic hydrocarbons (PAH) are a class of
common environmental pollutants that are produced by the
incomplete combustion of organic materials. Benzo[a]pyrene
is a widely studied PAH compound due to its potent carcino-
genic activity in animal models. The chemically unreactive
benzo[a]pyrene is metabolized in cells, forming reactive diol
epoxide derivatives that can bind covalently to DNA. Unre-
paired benzo[a]pyrene DNA adducts can lead to mutations
that may eventually result in cancer. The reactive and muta-
genic metabolites of benzo[a]pyrene are the (+)-7R,
8S,9S,10R-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide,
(+)-anti-BPDE and the ( )-7R,8S,9S,10R enantiomer, ( )-
anti-BPDE (1,2). DNA damage occurs mainly by the binding
of the C10 position of anti-BPDE tothe N
2 position of guanine,
thus forming the four stereoisomeric bulky adducts 10S (+)-
trans-anti-BPDE-N
2-dG, 10R (+)-cis-anti-BPDE-N
2-dG, 10R
( )-trans-anti-BPDE-N
2-dG and 10S ( )-cis-anti-BPDE-N
2-
dG (2,3). In vitro, the reaction of (+)-anti-BPDE with DNA
yields predominantly the (+)-trans-anti-BPDE-N
2-dG adduct,
while the reaction of ( )-anti-BPDE generates mainly the ( )-
trans-anti-BPDE-N
2-dG adduct (4). In cells, the major ben-
zo[a]pyrene DNA adduct is (+)-trans-anti-BPDE-N
2-dG (2).
The structures of the four anti-BPDE-N
2-dG adducts in
DNA have been solved by NMR spectroscopy (5). In a duplex
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the pyrenylresidues are not intercalated betweenadjacent base
pairs. Instead, in the case of the (+)-trans-anti-BPDE-N
2-dG
adduct, the aromatic pyrenyl residue stacks primarily over an
adjacent sugar ring in the complementary strand in the minor
groove, and is oriented toward the 50 end of the modiﬁed
strand. In the case of the ( )-trans-anti-BPDE-N
2-dG adduct,
the pyrenyl residue stacks mainly over a sugar ring in the
complementary strand in the minor groove, and is oriented
toward the 30 end of the modiﬁed strand (5–7). Thus, despite
their identical chemical structure, the stereoisomeric (+)- or
( )-trans-anti-BPDE-N
2-dG adducts adopt different conﬁg-
urations in duplex DNA as a result of the different absolute
conﬁgurations of substituents about the four chiral carbon
atoms. This difference, however, does not appear to affect
the efﬁciency of their removal by human nucleotide excision
repair in vitro (8).
BPDE DNA adducts are mutagenic in a variety of prokar-
yotic and eukaryotic cellular systems (9–15). However, the
molecular mechanism of BPDE-induced mutagenesis is not
well understood in eukaryotes. In cells, base damage-induced
mutagenesis is mainly mediated through error-prone transle-
sionsynthesis.Keystepsoftranslesionsynthesisinclude copy-
ing damaged sites of the template by specialized polymerases
during DNA replication. Conceptually, copying the lesion site
may be divided into two distinct steps: nucleotide insertion
opposite the lesion and extension synthesis from opposite the
lesion. Recent studies indicate that Polz and the Y family
polymerases are important translesion polymerases in eukar-
yotes [reviewed in Refs (16–20)]. In the yeast Saccharomyces
cerevisiae, the Y family consists of Polh and Rev1 (21).
Mammals contain two additional members of the Y family
polymerases: Polk and Poli (16,21).
Translesion synthesis can be error-free or error-prone.
Whereas error-prone translesion synthesis results in mutagen-
esis, error-free translesion synthesis suppresses mutagenesis.
Invitro,Polk effectively performs error-freetranslesionsynth-
esis in response to (+)- and ( )-trans-anti-BPDE-N
2-dG DNA
adducts (22–26), whereas human Polh is capable of error-
prone nucleotide insertion opposite these lesions (23,27–
29). In vivo,P o l k indeed plays an important role in suppres-
sing BPDE-induced mutagenesis (30), and is required for
recovery from the BPDE-induced S-phase checkpoint (31).
In yeast cells, there is evidence supporting a role for Polh
in error-pone translesion synthesis following exposure of
DNA to (±)-anti-BPDE (15). The majority of mutations
induced by (±)-anti-BPDE in yeast, however, is generated
through the Polz mutagenesis pathway that includes the
Rev1 protein (15). Similarly, mutagenesis following cellular
exposure to racemic (±)-anti-BPDE also requires Polz and
Rev1 in cultured human cells (32,33).
The treatment of plasmid DNA or cells with racemic
(±)-anti-BPDE yields several different types of DNA adducts.
Therefore, it is difﬁcult to deﬁne the roles of Polh, Polz and
Rev1 in BPDE-induced mutagenesis with DNA adducts of
deﬁned structure based on the treatment of DNA or cells
with racemic (±)-anti-BPDE. In order to understand BPDE
mutagenesis at a more deﬁned molecular level, we examined
in vivo translesion synthesis of two site-speciﬁc (+)- and ( )-
trans-anti-BPDE-N
2-dG adducts in yeast cells. In this report,
we show that while the Polz pathway is generally required for
translesion synthesis and mutagenesis of the (+)- and ( )-
trans-anti-BPDE-N
2-dG DNA adducts, Polh, Polz and Rev1
together are required for G!T transversion mutations, a major
type ofmutagenesisinducedby theselesions. Based oninvitro
biochemical and in vivo genetic results, we present mechan-
istic models of translesion synthesis and mutagenesis of these
two DNA adducts.
MATERIALS AND METHODS
Materials
T4 DNA ligase, the T4 gene 32 protein and T4 polynucleotide
kinase were obtained from Enzymax (Lexington, KY). Yeast
lytic enzyme (70000 U/g) was purchased from MP Biomedi-
cals (Irvine, CA). The Wizard PCR Preps DNA Puriﬁcation
Resin was from Promega (Wisconsin, WI). The Thermo
Sequenase kit was obtained from Amersham Pharmacia
Biotech (Piscataway, NJ). Oligonucleotides containing a
site-speciﬁc (+)-trans-anti-N
2-dG or a ( )-trans-anti-BPDE-
N
2-dG adduct was prepared as described previously (34–36).
Its sequence is 50-CTCGATCGCTAACGCTACCATCCGA-
ATTCGCCC-30, where the modiﬁed guanine is underlined.
Other DNA oligonucleotides were synthesized by Integrated
DNA Technologies (Coralville, IA).
Yeast strains
Yeast strains used were the wild-type BY4741 (MATa his3
leu2 met15 ura3) and the isogenic BY4741Drad30 (rad30
deletion mutant), BY4741Drev1 (rev1 deletion mutant),
BY4741Drev3 (rev3 deletion mutant) and BY4741
Drev3Drad30 (rev3 rad30 double deletion mutant). BY4741
was purchased from ATCC (Manassas, VA). BY4741Drad30
(lacking Polh) was purchased from Research Genetics
(Huntsville, AL). BY4741Drev1, BY4741Drev3 (lacking
Polz) and BY4741Drev3Drad30 were constructed as described
previously (15,37).
Construction of plasmids containing site-specific
(+)-trans-anti-BPDE-N
2-dG or ( )-trans-anti-
BPDE-N
2-dG adducts
Plasmids containing site-speciﬁc (+)-trans-anti-BPDE-N
2-dG
or ( )-trans-anti-BPDE-N
2-dG adducts were constructed by
Enzymax using a previously described method (37). Brieﬂy, a
20mer DNA oligonucleotide, 50-GTGCCCTCCATGGAAA-
AATC-30, was annealed to the single-stranded phagemid
pELUf1 vector at its unique NcoI restriction site within the
URA3 gene. Following digestion with the NcoI restriction
endonuclease, the linearized pELUf1 was annealed with a
62mer DNA scaffold, 50-CTGUGCCCUCCAUGGGGCGA-
AUTUGGAUGGUAGCGUTAGCGAUCGAGGAAAAAUC-
AGTCAAG-30, and the damaged 33mer oligonucleotide that
had been phosphorylated at the 50 end by T4 polynucleotide
kinase. While the mid region of the scaffold is complementary
to the damaged oligonucleotide, its ends are complementary to
the single stranded pELUf1 ends. The BPDE-modiﬁed oligo-
nucleotide was ligated into the pELUf1 vector by T4 DNA
ligase at 16 C for 20 h, and the DNA was precipitated in
ethanol. Finally, the complementary strand of pELUf1 was
synthesized with T4 DNA polymerase in the presence of
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dGTP and dUTP, using the scaffold as the primer. The result-
ing construct was a double-stranded plasmid containing a
site-speciﬁc (+)-trans-anti-BPDE-N
2-dG or ( )-trans-anti-
BPDE-N
2-dG adduct, in which the undamaged strand con-
tained U in place of T. Formation of double-stranded plasmid
pELUf1-BPDE was conﬁrmed by electrophoresis on a 1%
agarose gel.
In vivo translesion synthesis assays in yeast cells
In vivo translesion synthesis assays were performed according
to a previously described method (37) with modiﬁcations.
Brieﬂy, site-speciﬁcally damaged pELUf-BPDE plasmid
(2 mg) was transformed into yeast cells of various strains
by the lithium acetate method (38). Following transformation,
yeast cells were collected by centrifugation (20 s at
5000 r.p.m.) in a microcentrifuge. Cells were resuspended
in 400 ml of sterile water and were plated onto two YNB
minimal agar (0.17% yeast nitrogen base, 0.49% ammonium
sulfate, 2% glucose and 2% agar) plates lacking leucine but
supplemented with 5 mM 5-ﬂuoroorotic acid (5-FOA),
150 mM methionine and 380 mM uracil to score for colonies
containing replicated pELUf1-BPDE. Cells transformed by
the vector pELUf1 without the damaged oligonucleotide insert
remained URA3 wild-type and thus could not grow on plates
containing 5-FOA. After incubation at 30 C for 3–4 days,
yeast colonies were counted. In each experiment with each
strain, transformation efﬁciency was determined by a parallel
transformation using the undamaged and double-stranded
pELUf1. Translesion synthesis was calculated as transfor-
mants per mg of the damaged plasmid per 10
6 transformable
cells with the undamaged plasmid (i.e. transformants per mg
of the damaged plasmid · 10
6/transformation efﬁciency
expressed as transformants per mg of the undamaged plasmid).
Relative translesion synthesis was obtained by comparing
translesion synthesis in various mutant strains to that in the
wild-type cells.
Yeast colonies on the 5-FOA plates were individually resus-
pended in 10 ml of a solution containing 1 mg/ml yeast lytic
enzyme in sterile water. After incubation at 37 C for 1.5–2 h,
an aliquot of 1 ml was used for PCR ampliﬁcation of a 670 bp
plasmid region containing the original lesion site, using the
primers, 50-CCCGCAGAGTACTGCAATTTGAC and 50-
GAGCGGATAACAATTTCACACAGG. After heating the
PCR mixture (20 ml) at 94 C for 4 min, 35 cycles of ampli-
ﬁcationwere performed according tothe following conditions:
30 s denaturation at 94 C, 30 s annealing at 65 C, and 45 s
extension at 72 C. After the last cycle, the reaction was con-
tinuedfor7moreminat72 C.Analiquotof2mlPCRproducts
was separated by electrophoresis on a 1% agarose gel contain-
ing 0.5 mg/ml ethidium bromide. Ampliﬁed DNA was puriﬁed
by using the Wizard PCR Preps DNA Puriﬁcation Resin
according to the manufacturer’s instruction. The precise spe-
ciﬁcity of translesion synthesis opposite the lesion was deter-
mined by sequencing the PCR DNA fragment. Yeast colonies
that didnot yieldPCR productsand plasmid clonesthat didnot
contain the inserted oligonucleotide sequence were excluded
from the calculations. A few transformants by the empty vec-
tor pELUf1 escaped selection by the 5-FOA plates, probably
due to mutations somewhere in the vector URA3 gene.
RESULTS
The Polz pathway is the major mechanism for
translesion synthesis of the (+)- and ( )-trans-
anti-BPDE-N
2-dG adducts in yeast cells
An in vivo genetic assay slightly modiﬁed from that of Zhao
et al. (37) was used to examine translesion synthesis of a site-
speciﬁc (+)- or ( )-trans-anti-BPDE-N
2-dG adduct in yeast
cells. A 33mer oligonucleotide containing the site-speciﬁc
adduct was ligated into a single-stranded plasmid, which
was subsequently converted into the double-stranded form
by in vitro synthesis of the complementary strand using
dUTP instead of dTTP. After transformation of the site-
speciﬁcally damaged plasmid into cells, the complementary
strand was degraded as a result of extensive DNA strand
cleavage at sites of uracil by the sequential actions of a
uracil-DNA glycosylase and an AP endonuclease, converting
the plasmid DNA back into the single-stranded form (37). It is
thus expected that this assay speciﬁcally reﬂects translesion
synthesis without interference by DNA repair and template
switching mechanisms (37), both of which require double-
stranded DNA. The transformation efﬁciency was determined
byusingundamagedanddouble-strandedplasmidsinthesame
experiment. After normalizing for transformation efﬁciency,
the translesion synthesis efﬁciency in various cells relative to
that in the wild-type cells was calculated. Yeast colonies were
separately analyzed by PCR to recover a 670 bp region of the
replicatedplasmid.Thespeciﬁcityoftranslesionsynthesiswas
determinedbysequencingthePCR-ampliﬁedDNA fragments.
To examine the role of the Polz pathway in bypassing the
(+)- and ( )-trans-anti-BPDE-N
2-dG adducts, we performed
invivo translesion synthesisassays inyeastrev3 (lackingPolz)
and rev1 deletion mutant cells. In rev1 mutant cells, the trans-
lesion synthesis of the (+)-trans-anti-BPDE-N
2-dG adduct was
reduced to 49% of the wild-type level (P ¼ 0.005), while that
of the ( )-trans-anti-BPDE-N
2-dG adduct was reduced to
22% (Figure 1). In rev3 mutant cells, translesion synthesis
of the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts were
reduced to a greater extent between 16 and 6.5%, respectively,
of the wild-type levels (Figure 1). In wild-type cells, transle-
sion synthesis of the ( )-trans-anti-BPDE-N
2-dG adduct
occurred consistently at a slightly higher efﬁciency than
that of the (+)-trans-anti-BPDE-N
2-dG adduct by  1.3-fold.
These results show that the Polz pathway is the major mechan-
ism for translesion synthesis of the (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts in yeast cells.
Contribution of Polh to translesion synthesis of the
(+)- and ( )-trans-anti-BPDE-N
2-dG adducts in vivo
To determine whether Polh affects bypass of the (+)- and ( )-
trans-anti-BPDE-N
2-dG adducts in yeast cells, we performed
in vivo translesion synthesis assays in the rad30 deletion
mutant strain (lacking Polh). As shown in Figure 1, in the
absence of Polh, translesion synthesis of the (+)-trans-
anti-BPDE-N
2-dG adduct was reduced to 74% (±18%) of
the wild-type level (P ¼ 0.004), while that of the ( )-
trans-anti-BPDE-N
2-dG adduct was reduced to 63% (±6%).
Togaininsightsintothe geneticrelationshipbetweenPolhand
Polz in bypass of the (+)- and ( )-trans-anti-BPDE-N
2-dG
adducts, we examined translesion synthesis in rev3 rad30
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in Figure 1, translesion synthesis of either (+)- or ( )-trans-
anti-BPDE-N
2-dG in the double mutant cells was no more
deﬁcient than that in rev3 mutant strain. These results show
that Polh plays a minor role in translesion synthesis of the (+)-
and ( )-trans-anti-BPDE-N
2-dG adducts in yeast cells, and
suggest that Polh functions in the Polz pathway in response to
these lesions.
Mutagenic translesion synthesis in yeast cells of the (+)-
and( )-trans-anti-BPDE-N
2-dGadductspredominantly
results from A and G insertions opposite the lesions
To determine translesion synthesis products at a nucleotide
resolution, we ampliﬁed by PCR a 670 bp region surrounding
the original lesion site from individual yeast colonies, and
subsequently sequenced the ampliﬁed DNA fragments. In
wild-type cells, the majority of translesion synthesis resulted
from the correct C insertion opposite the (+)- (76%) and
( )-trans-anti-BPDE-N
2-dG (89%) adducts (Tables 1 and 2).
While 10 and 7.3% of A and G, respectively, were inserted
opposite (+)-trans-anti-BPDE-N
2-dG (Table 1), only 4% each
of A and G were inserted opposite ( )-trans-anti-BPDE-N
2-
dG (Table 2). Insertion of T, deletions, and tandem base
substitutions constituted very minor translesion synthesis pro-
ducts (Tables 1 and 2). Other types of translesion synthesis,
accounting for 3.6% and 0.9% for the (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts, respectively (Tables 1 and 2), resulted
from the correct C insertion opposite the lesion, but contained
mutations at adjacent sites (Figure 2). For simplicity, these are
referred to as untargeted mutagenesis products (Figure 2).
These results indicate that mutagenic translesion synthesis
Figure 1. Relativefrequenciesoftranslesionsynthesis(TLS)invariousyeaststrains.UsingtheplasmidpELUf1-BPDEcontainingasite-specific(+)-or( )-trans-
anti-N
2-dGadduct,invivotranslesionsynthesisassayswereperformedasdescribedinMaterialsandMethods.RelativeTLSwasobtainedbycomparingtranslesion
synthesisinvariousmutantstrainstothatinthewild-typecells.SlightlydifferenttransformationefficienciesasdeterminedwiththeundamagedpELUf1weretaken
into account in calculating the relative efficiencies. SDs are shown as error bars. WT, wild-type; rad30, lacking Polh; rev1, lacking Rev1; rev3, lacking Polz;
rev3rad30, lacking both Polz and Polh.
Table 1. Specificity of translesion synthesis opposite the (+)-trans-anti-BPDE-N
2-dG adduct in various yeast strains
Strain
a Clones sequenced
b Base incorporation Deletion
c Tandem substitution
d Others
e
C A G T Total
WT 137 104 (76%) 14 (10%) 10 (7.3%) 2 (1.5%) 130 (95%) 1 (0.7%) 1 (0.7%) 5 (3.6%)
rad30 74 58 (78%) 2 (2.7%) 13 (18%) — 73 (99%) — — 1 (1.4%)
rev1 45 42 (93%) 2 (4.4%) — — 44 (98%) 1 (2.2%) — —
rev3 54 51 (94%) 2 (3.7%) — — 54 (100%) — — —
rev3 rad30 31 28 (90%) — — — 28 (90%) — — 3 (10%)
aWT, wild-type; rad30, lacking Polh; and rev3, lacking Polz.
bNumberofindependent clonessequencedfollowingin vivotranslesionsynthesisassaysusingthedamagedpELUf1-BPDEplasmidscontaininga site-specific(+)-
trans-anti-BPDE-N
2-dG adduct.
cDeletionswere:50-CTCGATCGCTAACGCTACCATCCGAATTCGCCC-30 inwild-typecells,and50-CTCGATCGCTAACGCTACCATCCGAATTCGCCC-30
in rev1 mutant cells, where the damaged G is in boldface and the deleted sequence is underlined.
dThe tandem substitution product was: 50-CTCGATCGCTAACTTTACCATCCGAATTCGCCC-30, in which the damaged G and its 30 C were replaced by TT
(underlined).
eOther translesion synthesis was derived from the correct C insertion opposite the lesion plus mutations 30 or 50 of the lesion site, yielding untargeted mutagenesis
products. The sequences of these products are shown in Figure 2.
420 Nucleic Acids Research, 2006, Vol. 34, No. 2of the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts in yeast
cells predominantly results from A and G insertions opposite
the lesion, leading to G!T and G!C transversion mutations,
respectively; and that the (+)-trans-anti-BPDE-N
2-dG adduct
is more mutagenic than the ( )-trans-anti-BPDE-N
2-dG
adduct.
Contributions of Polz, Rev1 and Polh to the
mutagenic specificity of the (+)- and ( )-trans-
anti-BPDE-N
2-dG adducts
To gain insights into understanding the roles of Polz,R e v 1
and Polh in translesion synthesis of the (+)- and ( )-trans-
anti-BPDE-N
2-dG adducts, the bypass products were recov-
ered by PCR from the corresponding yeast mutant strains,
and the ampliﬁed DNA fragments were sequenced. Speciﬁcity
of translesion synthesis in the absence of these bypass
polymerases was then compared with that of the wild-type
cells. Without Polh, insertion of A was largely reduced oppo-
site the (+)-trans-anti-BPDE-N
2-dG adduct (Table 1), and
was not detected opposite the ( )-trans-anti-BPDE-N
2-dG
(Table 2). Additionally, insertion of G opposite the (+)-
trans-anti-BPDE-N
2-dG adduct was signiﬁcantly increased
(Table 1). Translesion synthesis in rev1 and rev3 (lacking
Polz) mutant cells yielded similar products. In rev3 mutant
cells, insertion of G opposite the lesion was not detected, and
insertionofAwassigniﬁcantlyreduced(Tables1and2).Simi-
larly, in rev1 mutant cells, insertion of A opposite the lesion
was signiﬁcantly reduced, and insertion of G was not detected
opposite the (+)-trans-anti-BPDE-N
2-dG or greatly reduced
opposite the ( )-trans-anti-BPDE-N
2-dG adduct (Tables 1
and 2). In the absence of both Polh and Polz (rev3 rad30
double mutant), insertions of A and G opposite the lesions
were abolished (Tables 1 and 2).
When the altered bypass in the mutant strains was directly
compared with the bypass of the (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts in wild-type cells, expressed as transle-
sion synthesis relative to that in wild-type cells, a major con-
tribution by Polh to A insertion and the general dependence
of mutagenesis on Rev1 and Polz were clearly seen (Tables 3
and 4). The effect of Polh on G incorporation, however, dif-
fered for (+)- versus ( )-trans-anti-BPDE-N
2-dG. In the
Table 2. Specificity of translesion synthesis opposite the ( )-trans-anti-BPDE-N
2-dG adduct in various yeast strains
Strain
a Clones sequenced
b Base incorporation Deletion Tandem substitution
c Others
d
C A G T Total
WT 222 198 (89%) 9 (4.1%) 9 (4.1%) 3 (1.4%) 219 (99%) — 1 (0.5%) 2 (0.9%)
rad30 88 84 (95%) — 2 (2.3%) — 86 (98%) — — 2 (2.3%)
rev1 63 61 (97%) 1 (1.6%) 1 (1.6%) — 63 (100%) — — —
rev3 41 40 (98%) 1 (2.4%) — — 41 (100%) — — —
rev3 rad30 40 40 (100%) — — — 40 (100%) — — —
aWT, wild-type; rad30, lacking Polh; and rev3, lacking Polz.
bNumber of independent clones sequenced following in vivo translesion synthesis assays using the damaged pELUf1-BPDE plasmids containing a site-specific
( )-trans-anti-BPDE-N
2-dG adduct.
cThe tandem substitution product was: 50-CTCGATCGCTAACTTTACCATCCGAATTCGCCC-30, in which the damaged G and its 30 C were replaced by TT
(underlined).
dOther translesion synthesis was derived from the correct C insertion opposite the lesion plus mutations 30 or 50 of the lesion site, yielding untargeted mutagenesis
products. The sequences of these products are shown in Figure 2.
Figure 2. Products of untargeted mutagenesis. The damaged 33mer oligonucleotide contained in the plasmid pELUf1-BPDE is denoted as the template for
translesion synthesis (TLS). Untargeted mutagenesis products resulting from TLS are shown below the damaged template. Strains from which the untargeted
mutagenesis products were recoveredare showntogether with the number of such mutantplasmid clones. The correct C insertion oppositethe lesion is indicatedin
blue,whilemutationsareillustratedinred.(A)Untargetedmutagenesisinthecaseofthe(+)-trans-anti-N
2-dGadduct.(B)Untargetedmutagenesisinthecaseofthe
( )-trans-anti-N
2-dG adduct. D, deletion; WT, wild-type; rad30, lacking Polh; rev3rad30, lacking both Polz and Polh.
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site the former lesion, but decreased  4-fold opposite the
latterlesion (Tables 3and4). Apparently,the untargeted muta-
genesis (Figure 2) induced by (+)- and ( )-trans-anti-BPDE-
N
2-dGadducts, which constitutedonlyavery minorfractionof
the overall translesion synthesis, required Polz and Rev1, but
was independent of the Polh function. As for error-free trans-
lesion synthesis, reﬂected by C insertion opposite the lesion,
Polh did not have a major impact. In contrast, such error-free
bypass signiﬁcantly depended on Rev1 and mostly required
the function of Polz (Tables 3 and 4).
Taken together, these results show that (i) Polh, Polz and
Rev1 combined are required for G!T mutagenesis induced
by the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts; and (ii)
G!C mutagenesis induced by these two lesions is generated
through the Polz pathway, independent of Polh opposite (+)-
trans-anti-BPDE-N
2-dG, but involving the Polh function
opposite ( )-trans-anti-BPDE-N
2-dG. Additionally, these
results suggest that the Polz pathway is the major mechanism,
while Polh plays a minor role, for error-free translesion synth-
esis of the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts.
DISCUSSION
Polh was originally discovered as an error-free translesion
synthesis polymerase in response to ultraviolet (UV)-
induced TT dimers (39,40). However, the ﬁrst clue suggesting
that this polymerase may be involved in error-prone transle-
sion synthesis of benzo[a]pyrene DNA adducts came from
biochemical studies using templates containing a site-
speciﬁc (+)-trans-anti-BPDE-N
2-dG adduct (27). Puriﬁed
Polh is able to recognize this bulky DNA lesion, and predo-
minantly inserts an A opposite the lesion (27). Similar studies
with the ( )-trans-anti-BPDE-N
2-dG adduct showed that this
lesion is less efﬁciently bypassed by Polh than the (+)-trans-
anti-BPDE-N
2-dG adduct (23,28,29). In this study, we tested
our hypothesis that Polh participates in error-prone translesion
synthesis by inserting A opposite the (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts. Using an in vivo genetic assay that is
based on the replication of site-speciﬁcally damaged plasmids
inyeastcells,weshowedthatPolhindeedplaysamajorrolein
the insertion of A opposite these two stereoisomeric lesions,
resulting in G!T transversion mutations. Therefore, in con-
trast to its anti-mutagenic role in response to UV radiation,
Polh functions to promote mutagenesis induced by the (+)-
and ( )-trans-anti-BPDE-N
2-dG DNA adducts.
Insertions of A opposite the (+)- and ( )-trans-anti-BPDE-
N
2-dG adducts are mostly abolished when either Polh, Polz or
Rev1 is absent. Thus, the induced G!T transversion muta-
tions depend on the functions of all these three proteins. Our
in vivo results are best explained by the two-polymerase two-
step mechanism of translesion synthesis (18,41). In such a
bypass pathway, A is inserted by Polh opposite the lesion
followed by extension synthesis catalyzed by Polz. Support-
ing this conclusion, A is effectively inserted opposite (+)- and
( )-trans-anti-BPDE-N
2-dG adducts by Polh in vitro
(15,23,27–29), but not by Rev1, or just barely by Polz
(15,42). However, puriﬁed Polh is ineffective in extension
synthesis from opposite these lesions (15,23,27,28). The
bypass intermediate is thus most likely extended by Polz.
According to this mechanism, the insertion step would not
occur without Polh and the extension step would not occur
without Polz, thus explaining the observed dependence on
both Polh and Polz of the G!T transversion mutations
induced by the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts.
A very weak activity is detectable for Polh to extend from
opposite the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts in
vitro (15,23,27,28). This marginal activity was most likely
responsible for the residual (5–10% of the wild-type level)
G!T transversion mutations in the absence of Polz (Tables 3
and 4). In the absence of Polh, a residual A insertion activity
was also observed opposite the (+)-trans-anti-BPDE-N
2-dG
adduct (Table 3), which probably resulted from the very
weak activity of A insertion by Polz (15). Supporting this
interpretation, the residual A insertion activity was eliminated
in cells lacking both Polh and Polz (Tables 3 and 4).
With respect to G!T transversion mutagenesis induced by
the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts, the pheno-
typeoftherev1mutantissimilartothatofrev3thatlacksPolz.
Since Rev1 is unable to insert an A opposite these adducts
(42), this protein must play a non-catalytic function for the
induced G!T mutagenesis, which is similar to its role in UV-
induced mutagenesis (42,43). So far, an in vivo catalytic activ-
ity (dCMP transferase) of Rev1 has been suggested only for
the bypass of APsites (37,43).Thus, the non-catalyticfunction
of Rev1 may be responsible for its ubiquitous role in transle-
sion synthesis in cells. The precise nature of this non-catalytic
function, however, remains unknown.
Table 3. Changes in translesion synthesis specificity opposite the (+)-trans-
anti-BPDE-N
2-dG adduct in mutant cells relative to that in wild-type cells
a
Strain
b Base incorporation Deletion Tandem
substitution
Others
c Total
CAGT
WT 0.76 0.10 0.07 0.02 0.01 0.01 0.01 1
rad30 0.58 0.02 0.13 — — — 0.01 0.74
rev1 0.46 0.02 — — 0.01 — — 0.49
rev3 0.15 0.01 — — — — — 0.16
rev3 rad30 0.17 — — — — — 0.02 0.19
aTranslesion synthesis in various mutant strains is expressed relative to that in
the wild-type strain. Calculations were based on Figure 1 and Table 1.
bWT, wild-type; rad30, lacking Polh; and rev3, lacking Polz.
cOther translesion synthesis yielded untargeted mutagenesis products, whose
sequences are shown in Figure 2.
Table 4. Changes in translesion synthesis specificity opposite the ( )-trans-
anti-BPDE-N
2-dG adduct in mutant cells relative to that in wild-type cells
a
Strain
b Base incorporation Deletion Tandem
substitution
Others
c Total
CAG T
WT 0.89 0.04 0.04 0.01 — 0.01 0.01 1
rad30 0.60 — 0.014 — — — 0.014 0.63
rev1 0.213 0.004 — — — — — 0.22
rev3 0.0637 0.0016 — — — — — 0.065
rev3 rad30 0.066 — — — — — — 0.066
aTranslesion synthesis in various mutant strains is expressed relative to that in
the wild-type strain. Calculations were based on Figure 1 and Table 2.
bWT, wild-type; rad30, lacking Polh; and rev3, lacking Polz.
cOther translesion synthesis yielded untargeted mutagenesis products, whose
sequences are shown in Figure 2.
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translesion synthesis is G insertion opposite the (+)- and ( )-
trans-anti-BPDE-N
2-dG adducts, leading to G!C trans-
version mutations, which requires the Polz pathway. Missing
either Polz or Rev1 abolishes this mode of translesion
synthesis. Opposite the (+)-trans-anti-BPDE-N
2-dG adduct,
Polz is capable of translesion synthesis and preferentially
inserts G in vitro (15), whereas puriﬁed Polh is inefﬁcient
in G insertion (15,23,27,28). Thus, we conclude that the
observed G!C transversion mutations are generated mainly
by Polz-catalyzed G insertion followed by Polz-catalyzed
extension through the Polz pathway, i.e. a one-polymerase
two-step mechanism. Supporting this conclusion, inacti-
vating Polh led to an increase in G!C mutagenesis,
probably due to the elimination of the competitive binding
of Polh to the template and Polh-catalyzed A insertion.
In the case of the ( )-trans-anti-BPDE-N
2-dG adduct, Polz
is also capable of translesion synthesis and preferentially
inserts G in vitro, but its activity is lower than in the case
of the stereoisomeric (+)-trans-anti-BPDE-N
2-dG lesion (15).
On the other hand, G insertion opposite ( )-trans-anti-BPDE-
N
2-dG catalyzed by yeast Polh is more active than opposite
(+)-trans-anti-BPDE-N
2-dG in vitro (15). Consistent with
these biochemicalresults, we observed thatG!Cmutagenesis
induced by ( )-trans-anti-BPDE-N
2-dG was signiﬁcantly
reduced in yeast cells in the absence of Polh (Table 4), sug-
gesting a major role for Polh in catalyzing G insertions oppo-
site this lesion. Thus, the precise mechanism of G!C
mutagenesis induced by the (+)-trans-anti-BPDE-N
2-dG
adduct is somewhat different from that induced by the
( )-trans-anti-BPDE-N
2-dG adduct, due to the different
catalytic selectivity of Polh.
Translesion synthesis of the (+)- and ( )-trans-anti-BPDE-
N
2-dG adducts in yeast cells results mainly in base incorpora-
tion opposite the lesions. Furthermore, most bypass products
result from the correct C insertion opposite the lesion, i.e.
error-free translesion synthesis. In vitro, Polh,P o l z and
Rev1 all have signiﬁcant C insertion activities opposite
these two lesions (15,23,27,28,42). In this study, we found
that C insertions opposite the lesions in vivo were only slightly
reduced in the absence of Polh, but were more signiﬁcantly
reduced in the absence of Rev1, and mostly abolished in the
absence of Polz (Tables 3 and 4). Therefore, error-free transle-
sion synthesis of these lesions is mostly performed by the Polz
pathway. The C insertion step is likely catalyzed by both Rev1
and Polz. Since Rev1 cannot perform extension synthesis fol-
lowing C insertion (42), the extension step must be catalyzed
by Polz. Consistent with this interpretation, error-free bypass
is most deﬁcient in yeast cells lacking Polz. Polh only makes a
minor contribution ( 30%) to error-free bypass of the (+)- and
( )-trans-anti-BPDE-N
2-dG adducts, for which the most
likelymechanismis Cinsertion by Polhand subsequent exten-
sion by Polz. A mechanistic model for translesion synthesis
and mutagenesis of the (+)- and ( )-trans-anti-BPDE-N
2-dG
adducts is summarized in Figure 3.
The results with the site-speciﬁc (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts in this study are in general agreement
with our earlier report on mutagenesis induced by racemic
(±)-anti-BPDE using randomly damaged plasmids (15). How-
ever, two differences are noted: quantitatively more G!C
Figure 3. Mechanistic models for translesion synthesis of the (+)- and ( )-trans-anti-N
2-dG DNA adducts in yeast cells. The (+)-and ( )-trans-anti-BPDE-N
2-dG
adducts strongly block the replication complex (represented by the filled blue oval). Translesion synthesis is mediated predominantly by C insertion opposite the
lesion catalyzed by the Rev1 dCMP transferase and by Polz. Extension synthesis by Polz completes the lesion bypass. Polh makes a minor contribution ( 30%) to
error-freebypass,forwhichthemostlikelymechanismisCinsertionbyPolhandsubsequentextensionbyPolz.Lessfrequently,Aisinsertedoppositethelesionby
Polh, which is subsequently extended by Polz, leading to G!T transversion mutations. Insertion of G opposite the lesions occurred at a low frequency, which is
catalyzed by Polz in the case of the (+)-trans-anti-BPDE-N
2-dG adduct and by Polz and Polh in the case of the ( )-trans-anti-BPDE-N
2-dG adduct. Subsequent
extensioniscatalyzedbyPolz,leadingto G!C transversionmutations.Rev1likelyfacilitatesPolz-catalyzedextension.Inthisrole,Rev1mayplaya non-catalytic
function independent of its dCMP transferase.
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in the randomly damaged system (15). Two factors may be
responsible for these differences. First, treatment of DNA with
(±)-anti-BPDE yields multiple types of lesions. In addition to
the (+)- and ( )-trans-anti-BPDE-N
2-dG adducts, the (+)- and
( )-cis-anti-BPDE-N
2-dG adducts and other minor BPDE
adducts are also formed (2,4). These additional forms of
DNA lesions likely contribute to the mutation spectrum. Sec-
ondly, deletions and insertions induced by (±)-anti-BPDE
occur more frequently within single nucleotide repeats (15).
The (+)- and ( )-trans-anti-BPDE-N
2-dG adducts in this
study, however, were not positioned within such repeat
sequences. Consequently, it is expected that frameshift
mutagenesis is less likely to occur in the sequence context
examined in this study.
Our studies further suggest that the (+)-trans-anti-BPDE-
N
2-dG adduct is more mutagenic than the ( )-trans-anti-
BPDE-N
2-dG adduct. Since the two lesions did not differ
greatly in translesion synthesis efﬁciency, the less mutagenic
property of the ( )-trans-anti-BPDE-N
2-dG adduct is likely a
direct result of its more frequent error-free bypass in cells. A
greatermutagenic potentialofthe(+)-trans-anti-BPDE-N
2-dG
adduct was also reported in cultured simian kidney cells in
different sequence contexts (12). Hence, the mutagenecity of
the BPDE adduct is inﬂuenced by its stereochemistry. More-
over, the speciﬁcity of nucleotide incorporation opposite the
(+)- and ( )-trans-anti-BPDE-N
2-dG adducts in these mam-
malian cells was similar to that reported here in yeast cells.
Recently, it was reported that (±)-anti-BPDE-induced muta-
genesis in cultured human cells is largely abolished when Polz
and REV1 expressions are suppressed (32,33). These simila-
rities suggest that the fundamental mechanism of translesion
synthesis and mutagenesis of the (+)- and ( )-trans-anti-
BPDE-N
2-dG adducts is conserved from yeast to mammals.
By comparing results using the same experimental system, it
is possible for us to evaluate the intrinsic mutagenic
potential of various DNA lesions. Thus, it is apparent that
the p-benzoquinone DNA adducts derived from benzene
are intrinsically much more potent in mutagenesis than the
(+)- and ( )-trans-anti-BPDE-N
2-dG adducts in yeast (44).
ACKNOWLEDGEMENTS
We thank Zhongwen Xie for technical assistance. This work
was supported by NIH grants CA92528 (to Z.W.), and
CA20851 (to N.E.G.). Funding to pay the Open Access pub-
lication charges for this article was provided by the NIH grant
CA92528.
Conflict of interest statement. None declared.
REFERENCES
1. Phillips,D.H.andGrover,P.L.(1994)Polycyclichydrocarbonactivation:
bay regions and beyond. Drug Metab. Rev., 26, 443–467.
2. Peltonen,K. and Dipple,A. (1995) Polycyclic aromatic hydrocarbons:
chemistryofDNAadductformation.J.Occup.Environ.Med.,37,52–58.
3. Cheng,S.C., Hilton,B.D., Roman,J.M. and Dipple,A. (1989) DNA
adducts from carcinogenic and noncarcinogenic enantiomers of
benzo[a]pyrene dihydrodiol epoxide. Chem. Res. Toxicol., 2,
334–340.
4. Cheng,S.C., Hilton,B.D., Roman,J.M. and Dipple,A. (1989) DNA
adducts from carcinogenic and noncarcinogenic enantiomers of
benzo[a]pyrene dihydrodiol epoxide. Chem. Res. Toxicol., 2,
334–340.
5. Geacintov,N.E., Cosman,M., Hingerty,B.E., Amin,S., Broyde,S. and
Patel,D.J. (1997) NMR solution structures of stereoisometric covalent
polycyclic aromatic carcinogen-DNA adduct: principles, patterns, and
diversity. Chem. Res. Toxicol., 10, 111–146.
6. Cosman,M., de los Santos,C., Fiala,R., Hingerty,B.E., Singh,S.B.,
Ibanez,V., Margulis,L.A., Live,D., Geacintov,N.E., Broyde,S. et al.
(1992)Solutionconformationofthemajoradductbetweenthecarcinogen
(+)-anti-benzo[a]pyrene diol epoxide and DNA. Proc. Natl Acad. Sci.
USA, 89, 1914–1918.
7. de los Santos,C., Cosman,M., Hingerty,B.E., Ibanez,V., Margulis,L.A.,
Geacintov,N.E., Broyde,S. and Patel,D.J. (1992) Influence of
benzo[a]pyrenediolepoxidechiralityonsolutionconformationsofDNA
covalent adducts: the ( )-trans-anti-[BP]G.C adduct structure and
comparison with the (+)-trans-anti-[BP]G.C enantiomer. Biochemistry,
31, 5245–5252.
8. Hess,M.T., Gunz,D., Luneva,N., Geacintov,N.E. and Naegeli,H. (1997)
Base pair conformation-dependent excision of benzo[a]pyrene diol
epoxide-guanine adducts by human nucleotide excision repair enzymes.
Mol. Cell. Biol., 17, 7069–7076.
9. Mackay,W., Benasutti,M., Drouin,E. and Loechler,E.L. (1992)
Mutagenesis by (+)-anti-B[a]P-N
2-Gua, the major adduct of
activated benzo[a]pyrene, when studied in an Escherichia coli
plasmid using site-directed methods. Carcinogenesis, 13,
1415–1425.
10. Jelinsky,S.A., Liu,T., Geacintov,N.E. and Loechler,E.L. (1995) The
major, N
2-Gua adduct of the (+)-anti-benzo[a]pyrene diol epoxide is
capable of inducing G!A and G!C, in addition to G!T, mutations.
Biochemistry, 34, 13545–13553.
11. Shukla,R., Liu,T., Geacintov,N.E. and Loechler,E.L. (1997) The major,
N
2-dG adduct of (+)-anti-B[a]PDE shows a dramatically different
mutagenic specificity (predominantly, G!A) in a 50-CGT-30 sequence
context. Biochemistry, 36, 10256–10261.
12. Moriya,M.,Spiegel,S., Fernandes,A., Amin,S., Liu,T.,Geacintov,N. and
Grollman,A.P. (1996) Fidelity of translesional synthesis past
benzo[a]pyrene diol epoxide-20-deoxyguanosine DNA adducts: marked
effects of host cell, sequence context, and chirality. Biochemistry, 35,
16646–16651.
13. Page,J.E.,Zajc,B.,Oh-hara,T.,Lakshman,M.K.,Sayer,J.M.,Jerina,D.M.
and Dipple,A. (1998) Sequence context profoundly influences the
mutagenic potency of trans-opened benzo[a]pyrene 7,8-diol
9,10-epoxide-purine nucleoside adducts in site-specific mutation
studies. Biochemistry, 37, 9127–9137.
14. Fernandes,A., Liu,T., Amin,S., Geacintov,N.E., Grollman,A.P. and
Moriya,M. (1998) Mutagenic potential of stereoisomeric bay
region (+)- and ( )-cis-anti-benzo[a]pyrene diol epoxide-N
2-20-
deoxyguanosine adducts in Escherichia coli and simian
kidney cells. Biochemistry, 37, 10164–10172.
15. Xie,Z., Braithwaite,E., Guo,D., Zhao,B., Geacintov,N.E. and Wang,Z.
(2003) Mutagenesis of benzo[a]pyrene diol epoxide in yeast:
Requirement for DNA polymerase z and involvement of DNA
polymerase h. Biochemistry, 42, 11253–11262.
16. Ohmori,H., Friedberg,E.C., Fuchs,R.P.P., Goodman,M.F., Hanaoka,F.,
Hinkle,D., Kunkel,T.A., Lawrence,C.W., Livneh,Z., Nohmi,T. et al.
(2001) The Y-family of DNA polymerases. Mol. Cell, 8, 7–8.
17. Wang,Z. (2001) Translesion synthesis by the UmuC family of DNA
polymerases. Mutat. Res., 486, 59–70.
18. Wang,Z. (2001) DNA damage-induced mutagenesis: a novel target for
cancer prevention. Mol. interv., 1, 269–281.
19. Livneh,Z. (2001) DNA damage control by novel DNA polymerases:
translesion replication and mutagenesis. J. Biol. Chem., 276,
25639–25642.
20. Friedberg,E.C., Fischhaber,P.L. and Kisker,C. (2001) Error-prone DNA
polymerases: novel structures and the benefits of infidelity. Cell, 107,
9–12.
21. Burgers,P.M., Koonin,E.V., Bruford,E., Blanco,L., Burtis,K.C.,
Christman,M.F., Copeland,W.C., Friedberg,E.C., Hanaoka,F.,
Hinkle,D.C. et al. (2001) Eukaryotic DNA polymerases: proposal for a
revised nomenclature. J. Biol. Chem., 276, 43487–43490.
22. Zhang,Y., Yuan,F., Wu,X., Wang,M., Rechkoblit,O., Taylor,J.-S.,
Geacintov,N.E. and Wang,Z. (2000) Error-free and error-prone lesion
424 Nucleic Acids Research, 2006, Vol. 34, No. 2bypass by human DNA polymerase k in vitro. Nucleic Acids Res., 28,
4138–4146.
23. Rechkoblit,O., Zhang,Y., Guo,D., Wang,Z., Amin,S., Krzeminsky,J.,
Louneva,N.andGeacintov,N.E.(2002)trans-Lesionsynthesispastbulky
benzo[a]pyrenediolepoxideN
2-dGandN
6-dAlesionscatalyzedbyDNA
bypass polymerases. J. Biol. Chem., 277, 30488–30494.
24. Zhang,Y., Wu,X., Guo,D., Rechkoblit,O. and Wang,Z. (2002) Activities
of human DNA polyemrase k in response to the major benzo[a]pyrene
DNAadduct:error-freebypassandextensionsynthesisfromoppositethe
lesion. DNA Repair, 1, 559–569.
25. Suzuki,N.,Ohashi,E.,Kolbanovskiy,A.,Geacintov,N.E.,Grollman,A.P.,
Ohmori,H. and Shibutani,S. (2002) Translesion synthesis by human
DNA polymerase k on a DNA template containing a single
stereoisomer of dG-(+)- or dG-( )-anti-N
2-BPDE (7,8-dihydroxy-anti-
9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene). Biochemistry, 41,
6100–6106.
26. Huang,X., Kolbanovskiy,A., Wu,X., Zhang,Y., Wang,Z., Zhuang,P.,
Amin,S. and Geacintov,N.E. (2003) Effects of base sequence context on
translesion synthesis past a bulky (+)-trans-anti-B[a]P-N
2-dG lesion
catalyzed by the Y-family polymerase pol k. Biochemistry, 42,
2456–2466.
27. Zhang,Y., Yuan,F., Wu,X., Rechkoblit,O., Taylor,J.-S., Geacintov,N.E.
and Wang,Z. (2000) Error-prone lesion bypass by human DNA
polymerase h. Nucleic Acids Res., 28, 4717–4724.
28. Zhang,Y., Wu,X., Guo,D., Rechkoblit,O., Geacintov,N.E. and Wang,Z.
(2002)Two-steperror-pronebypassofthe(+)-and( )-trans-anti-BPDE-
N
2-dG adducts by human DNA polymerases h and k. Mutat. Res., 510,
23–35.
29. Chiapperino,D., Kroth,H., Kramarczuk,I.H., Sayer,J.M., Masutani,C.,
Hanaoka,F., Jerina,D.M. and Cheh,A.M. (2002) Preferential
misincorporation of purine nucleotides by human DNA polymerase h
oppositebenzo[a]pyrene7,8-diol9,10-epoxidedeoxyguanosineadducts.
J. Biol. Chem., 277, 11765–11771.
30. Ogi,T., Shinkai,Y., Tanaka,K. and Ohmori,H. (2002) Polk protects
mammalian cells against the lethal and mutagenic effects of
benzo[a]pyrene. Proc. Natl Acad. Sci. USA, 99, 15548–15553.
31. Bi,X.,Slater,D.M.,Ohmori,H.andVaziri,C.(2005)DNApolymerasekis
specifically required for recovery from the benzo[a]pyrene-dihydrodiol
epoxide (BPDE)-induced S-phase checkpoint. J. Biol. Chem., 280,
22343–22355.
32. Li,Z., Zhang,H., McManus,T.P., McCormick,J.J., Lawrence,C.W. and
Maher,V.M. (2002) hREV3 is essential for error-prone translesion
synthesis past UV or benzo[a]pyrene diol epoxide-induced DNA lesions
in human fibroblasts. Mutat. Res., 510, 71–80.
33. Mukhopadhyay,S., Clark,D.R., Watson,N.B., Zacharias,W. and
McGregor,W.G. (2004) REV1 accumulates in DNA damage-induced
nuclear foci in human cells and is implicated in mutagenesis by
benzo[a]pyrenediolepoxide. Nucleic Acids Res., 32, 5820–5826.
34. Cosman,M., Ibanez,V., Geacintov,N.E. and Harvey,R.G. (1990)
Preparation and isolation of adducts in high yield derived from the
binding of two benzo[a]pyrene-7,8-dihydroxy-9,10-oxide stereoisomers
to the oligonucleotide d(ATATGTATA). Carcinogenesis, 11,
1667–1672.
35. Geacintov,N.E., Cosman,M., Mao,B., Alfano,A., Ibanez,V. and
Harvey,R.G. (1991) Spectroscopic characteristics and site I/site II
classification of cis and trans benzo[a]pyrene diolepoxide enantiomer-
guanosine adducts in oligonucleotides and polynucleotides.
Carcinogenesis, 12, 2099–2108.
36. Rechkoblit,O., Amin,S. and Geacintov,N.E. (1999) Primer length
dependence of binding of DNA polymerase I Klenow fragment to
template-primer complexes containing site-specific bulky lesions.
Biochemistry, 38, 11834–11843.
37. Zhao,B., Xie,Z., Shen,H. and Wang,Z. (2004) Role of DNA polymerase
h in the bypass of abasic sites in yeast cells. Nucleic Acids Res., 32,
3984–3994.
38. Becker,D.M. and Guarente,L. (1991) High-efficiency transformation of
yeast by electroporation. Methods Enzymol., 194, 182–187.
39. Johnson,R.E., Prakash,S. and Prakash,L. (1999) Efficient bypass of a
thymine-thymine dimer by yeast DNA polymerase, Polh. Science, 283,
1001–1004.
40. Masutani,C., Araki,M., Yamada,A., Kusumoto,R., Nogimori,T.,
Maekawa,T., Iwai,S. and Hanaoka,F. (1999) Xeroderma pigmentosum
variant (XP-V) correcting protein from HeLa cells has a thymine dimer
bypass DNA polymerase activity. EMBO J., 18, 3491–3501.
41. Wang,Z. (2005) Mechanism of bypass polymerases in eukaryotes.
In Siede,W., Kow,Y.W. and Doetsch,P.W. (eds), DNA Damage
Recognition. CRC Press, NY, pp. 475–493.
42. Zhang,Y., Wu,X., Rechkoblit,O., Geacintov,N.E., Taylor,J.-S. and
Wang,Z. (2002) Response of human REV1 to different DNA damage:
preferential dCMP insertion opposite the lesion. Nucleic Acids Res., 30,
1630–1638.
43. Nelson,J.R., Gibbs,P.E., Nowicka,A.M., Hinkle,D.C. and
Lawrence,C.W. (2000) Evidence for a second function for
Saccharomyces cerevisiae Rev1p. Mol. Microbiol., 37,
549–554.
44. Xie,Z., Zhang,Y., Guliaev,A.B., Shen,H., Hang,B., Singer,B. and
Wang,Z.(2005)Thep-benzoquinoneDNAadductsderivedfrombenzene
are highly mutagenic. DNA Repair, 4, 1399–1409.
Nucleic Acids Research, 2006, Vol. 34, No. 2 425